Conatus Pharmaceuticals (CNAT) Shares Pop Higher on Positive Zika Virus Mention
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
UPDATE - The article notes Zika virus therapies recently published in the journal Nature Medicine.
Conatus has several patents for the liver-disease drug emricasan, which couldbe used as a potential treatment. Some of the patents don't expire until 2028.
Conatus is up 18 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Buffalo Wild Wings (BWLD) November 135 straddle priced for movement of 10.4%
- Volatility and Volume movement
- Stocks with Implied Volatility Movement
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!